14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.005 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Protection against pneumococcal nasopharyngeal colonization in mice immunized with PspC (“Pneumococcal Surface Protein C”)-based vaccines formulated with whole bacteria as carriers or adjuvants M. De Lúcia Hernani, D. M. Ferreira, P. C. D. Ferreira, A. T. Moreno, E. Miyaji, P. Ho, M. L. Sarno de Oliveira Instituto Butantan, Sao Paulo, Brazil Background: Streptococcus pneumoniae (pneumococcus) is responsible for the majority of pneumonia cases around the world. Despite the effectiveness of conjugate vaccines, the costs of the available formulations are prohibitive for mass vaccination in developing countries. Protein antigens are alternatives for the constitution of low costs-formulations that can elicit immunity to different pneumococcal serotypes. PspC is a virulence factor that plays a role in the adhesion of the pathogen to epithelial cells and evasion from the immune system. Intact bacteria display adjuvant activities when administered in association with antigens, through the binding of their components to receptors present on immune cells surface. Methods: In this work, mucosal vaccines composed of PspC and two different bacteria as carriers and/or adjuvants were tested in mice. The first strategy consisted in Lactobacillus casei expressing PspC (L. casei-PspC), as a live vaccine. The second consisted in the combination of recombinant PspC with the whole cell pertussis vaccine (WCPV). Results: Nasal immunization of mice with L. casei-PspC did not stimulate the production of systemic and mucosal anti-PspC antibodies. Despite the absence of specific antibodies, this vaccine inhibited pneumococcal nasopharyngeal colonization of immunized mice, when compared with mice inoculated with saline or L. casei. In this same model, sublingual immunization with L. casei-PspC did not produce a significant effect on pneumococcal colonization. On the other hand, nasal immunization with PspC-WCPV induced high levels of anti-PspC antibodies. Mice immunized with PspC-WCPV presented a significant inhibition of pneumococcal colonization, when compared with mice inoculated with saline or WCPV. The reduction in pneumococcal colonization was much more accentuated for the PspC-WCPV formulation than for L. casei-PspC. Analysis of cytokine secretion by spleen cells from mice 5 days after the colonization challenge showed two different patterns. Mice immunized with L. casei-PspC displayed a dramatic reduction in IFN-g and TNF-a secretion whereas mice immunized with PspC-WCPV displayed increased IFN-g and IL-17 secretion. Conclusion: Our results indicate that two different mechanisms are likely to be involved in the protection elicited by both vaccines. The mechanisms elicited by PspC-WCPV seem to be more effective in the control of pneumococcal nasopharyngeal carriage. Financial support: FAPESP, CNPq, Fundação Butantan.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.006 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Immunogenicity of interleukin 12 and DNA vaccine prime-BCG boost against Mycobacterium tuberculosis L. Bao, L. Gao, Y. Bao Sichuan University, Chengdu, China Background: BCG as an only effective vaccine to TB played variable efficacy. New vaccination strategies are required. We used interleukin 12 with the combined DNA prime-BCG boost strategies to observe whether the immunogenicity of vaccines against M.Tuberculosis would be improved. Methods: Plasmid pcDNA- Ag85A and pc-Esat-6 were constructed for vaccination . The mice were divided into 4 immunity groups: BCG group(1), DNA/BCG group(2), DNA+IL- 12/BCG group(3) and DNA/BCG+IL-12 group(4). All mice received three immunizations at 2- week interval For prime-boost experiments, animals were twice vaccinated intramuscular injection with combined DNA (Ag85A and ESAT-6) or mixed DNA-IL-12 and combined DNA, then boosted with BCG or mixed with DNA-IL-12 and BCG. ELISA was used to determine IgG antibody specificity and the proliferative responses of lymphocytes and the phenotype was detected by flow cytometry. Production of INF- was detected at 4-week, 6-week, and 8-week after boost. Results: The antibody titer of group 1, group 2, group 3 and group4 showed a positive reaction. Group3 and 4 compared with group2 and 1, induced high antibody titer. The antibody titer of all four groups increased gradually, and achieved a higher level at 8 week after booster. Group 1, group 2, group 3and group4 all showed significant difference of proliferative responses (P
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194: When citing these abstracts please
Page 243: When citing these abstracts please
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?